Squibb Company (NYSE:BMY) today announced that study results on
investigational agents Opdivo (nivolumab), a PD-1 immune
checkpoint inhibitor, elotuzumab, an antibody targeted against Signaling
Lymphocyte Activation Molecule (SLAMF7), ulocuplumab, an anti-CXCR4
antibody, and Sprycel (dasatinib), will be featured in oral
presentations at the 56th annual meeting of the American Society for
Hematology (ASH) in San Francisco from December 6-9, 2014.
for - Multiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hematology (ASH) Meeting investment picks